• Je něco špatně v tomto záznamu ?

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

P. Harter, G. Bogner, L. Chiva, D. Cibula, N. Concin, C. Fotopoulou, A. Gonzalez-Martin, F. Guyon, V. Heinzelmann-Schwarz, F. Kridelka, S. Mahner, F. Marmé, C. Marth, P. Morice, Z. Novák, A. Papadia, I. Ray-Coquard, M. Redecha, A. Redondo, R....

. 2024 ; 111 (3) : 277-284. [pub] 20230324

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007025

An international joint statement about the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer was published in 2016, warning about the uncritical use of HIPEC outside controlled studies. This statement has now been updated after the most recent literature was reviewed by the participating study groups and societies. HIPEC became a treatment option in patients with advanced colon cancer after positive results of a randomized trial comparing surgery and HIPEC versus palliative treatment alone. Although this trial did not compare the added value of HIPEC to surgery alone, HIPEC for the treatment of peritoneal metastases was in the subsequent years generalized to many other cancer types associated with peritoneal carcinomatosis including epithelial ovarian cancer (EOC). In the meantime, new evidence from prospective randomized trials specifically for EOC-patients emerged, with however contradicting results and several quality aspects that made the interpretation of their findings critical. Moreover, three additional trials in colorectal cancer failed to confirm the previously presumed survival benefit through the implementation of HIPEC in peritoneally disseminated colorectal cancers. Based on a still unclear and inconsistent landscape, the authors conclude that HIPEC should remain within the remit of clinical trials for EOC-patients. Available evidence is not yet sufficient to justify its broad endorsement into the routine clinical practice.

2 department of gynaecology and obstetrics University Hospital Bratislava Comenius University Bratislava Slovakia

Centre Léon Bérard Lyon France

Department of Gynaecology National Insitute of Oncology Budapest Hungary

Department of Gynecologic Oncology Medical Faculty Mannheim Heidelberg University Mannheim Germany

Department of Gynecology and Gynecologic Oncology Ev Kliniken Essen Mitte Henricistrasse 92 45136 Essen Germany

Department of Gynecology and Obstetrics Ospedale Regionale di Lugano EOC Lugano Switzerland

Department of Gynecology with Center of Gynecological Oncology Charité University Medicine of Berlin Berlin Germany

Department of Obstetrics and Gynaecology CHU de Liège Liège Belgium

Department of Obstetrics and Gynecology Clinica Universidad de Navarra Madrid Spain

Department of Obstetrics and Gynecology General University Hospital Prague 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Obstetrics and Gynecology Medical University Innsbruck Innsbruck Austria

Department of Obstetrics and Gynecology Paracelsus Medical University Salzburg Salzburg Austria

Department of Obstetrics and Gynecology University Hospital LMU Munich Munich Germany

Departments of Surgery and Cancer Faculty of Medicine Imperial College London London UK

Division of General Gynecology and Gynecologic Oncology Department of Obstetrics and Gynecology Gynecologic Cancer Unit Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Division of Gynaecological Oncology University Hospitals Leuven Leuven Belgium

Faculty of Biomedical Sciences Università della Svizzera Italiana Lugano Switzerland

Institut Bergonié Bordeaux France

Institut Gustave Roussy Villejuif France

Medical Oncology Department Clínica Univerdad de Navarra Madrid and Program in Solid Tumours CIMA Pamplona Spain

Medical Oncology Department Hospital Universitario La Paz IdiPAZ Madrid Spain

University Hospital Basel Basel Switzerland

University Hospital Geneva Geneva Switzerland

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007025
003      
CZ-PrNML
005      
20240423155652.0
007      
ta
008      
240412s2024 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bulcan.2023.02.011 $2 doi
035    __
$a (PubMed)36967330
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Harter, Philipp $u Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany. Electronic address: p.harter@kem-med.com
245    10
$a Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer / $c P. Harter, G. Bogner, L. Chiva, D. Cibula, N. Concin, C. Fotopoulou, A. Gonzalez-Martin, F. Guyon, V. Heinzelmann-Schwarz, F. Kridelka, S. Mahner, F. Marmé, C. Marth, P. Morice, Z. Novák, A. Papadia, I. Ray-Coquard, M. Redecha, A. Redondo, R. Schwameis, J. Sehouli, M. Undurraga, T. Van Gorp, I. Vergote
520    9_
$a An international joint statement about the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer was published in 2016, warning about the uncritical use of HIPEC outside controlled studies. This statement has now been updated after the most recent literature was reviewed by the participating study groups and societies. HIPEC became a treatment option in patients with advanced colon cancer after positive results of a randomized trial comparing surgery and HIPEC versus palliative treatment alone. Although this trial did not compare the added value of HIPEC to surgery alone, HIPEC for the treatment of peritoneal metastases was in the subsequent years generalized to many other cancer types associated with peritoneal carcinomatosis including epithelial ovarian cancer (EOC). In the meantime, new evidence from prospective randomized trials specifically for EOC-patients emerged, with however contradicting results and several quality aspects that made the interpretation of their findings critical. Moreover, three additional trials in colorectal cancer failed to confirm the previously presumed survival benefit through the implementation of HIPEC in peritoneally disseminated colorectal cancers. Based on a still unclear and inconsistent landscape, the authors conclude that HIPEC should remain within the remit of clinical trials for EOC-patients. Available evidence is not yet sufficient to justify its broad endorsement into the routine clinical practice.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a epiteliální ovariální karcinom $x patologie $7 D000077216
650    _2
$a hypertermická intraperitoneální peroperační chemoterapie $7 D000084262
650    _2
$a prospektivní studie $7 D011446
650    12
$a indukovaná hypertermie $x metody $7 D006979
650    12
$a nádory vaječníků $x farmakoterapie $x patologie $7 D010051
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
651    _2
$a Rakousko $7 D001317
651    _2
$a Švýcarsko $7 D013557
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bogner, Gerhard $u Department of Obstetrics and Gynecology, Paracelsus Medical University Salzburg, Salzburg, Austria
700    1_
$a Chiva, Luis $u Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain
700    1_
$a Cibula, David $u Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Concin, Nicole $u Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany; Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
700    1_
$a Fotopoulou, Christina $u Departments of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
700    1_
$a Gonzalez-Martin, Antonio $u Medical Oncology Department Clínica Univerdad de Navarra, Madrid, and Program in Solid Tumours CIMA, Pamplona, Spain
700    1_
$a Guyon, Frederic $u Institut Bergonié, Bordeaux, France
700    1_
$a Heinzelmann-Schwarz, Viola $u University Hospital Basel, Basel, Switzerland
700    1_
$a Kridelka, Frederic $u Department of Obstetrics and Gynaecology, CHU de Liège, Liège, Belgium
700    1_
$a Mahner, Sven $u Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
700    1_
$a Marmé, Frederik $u Department of Gynecologic Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
700    1_
$a Marth, Christian $u Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
700    1_
$a Morice, Philippe $u Institut Gustave-Roussy, Villejuif, France
700    1_
$a Novák, Zoltán $u Department of Gynaecology, National Insitute of Oncology, Budapest, Hungary
700    1_
$a Papadia, Andrea $u Department of Gynecology and Obstetrics, Ospedale Regionale di Lugano EOC, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
700    1_
$a Ray-Coquard, Isabelle $u Centre Léon Bérard, Lyon, France
700    1_
$a Redecha, Mikuláš $u II. department of gynaecology and obstetrics, University Hospital Bratislava, Comenius University, Bratislava, Slovakia
700    1_
$a Redondo, Andres $u Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
700    1_
$a Schwameis, Richard $u Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Sehouli, Jalid $u Department of Gynecology with Center of Gynecological Oncology,Charité, University Medicine of Berlin, Berlin, Germany
700    1_
$a Undurraga, Manuela $u University Hospital Geneva (HUG), Geneva, Switzerland
700    1_
$a Van Gorp, Toon $u Division of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Vergote, Ignace $u Division of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium
773    0_
$w MED00000917 $t Bulletin du cancer $x 1769-6917 $g Roč. 111, č. 3 (2024), s. 277-284
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36967330 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155648 $b ABA008
999    __
$a ok $b bmc $g 2081185 $s 1216792
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 111 $c 3 $d 277-284 $e 20230324 $i 1769-6917 $m Bulletin du cancer $n Bull Cancer $x MED00000917
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...